Dr Lal Pathlabs has informed that currently there is no such announcement or price sensitive information, which is pending to be intimated by the Company to the Stock Exchanges concerning its performance/operations required to be disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The spurt in volume of the scrip of the Company in recent past is absolutely market driven and the Company has no comments to offer on this. The company reiterated and clarified that all the information furnished by the Company is in public domain and the Company will comply with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and keep the Stock Exchanges duly informed of all the price sensitive information(s).
The above information is a part of company’s filings submitted to BSE.
